Hippo Signaling Pathway in Companion Animal Diseases, an Under Investigated Signaling Cascade

Overview

Journal Vet Q

Specialty Veterinary Medicine

Date 2021 May 4

PMID 33945400

Authors

Shaydee J Budel

Marloes M Penning

Louis C Penning

Affiliations

Soon will be listed here.

Abstract

The Hippo pathway is a highly conserved kinase cascade in mammals with the proteins YAP and TAZ as its most important downstream effectors that shuttle between cytoplasma and nucleus. It has a crucial role in processes such as embryogenesis, organ size control, homeostasis and tissue regeneration, where mechanosensing and/or cell-cell interactions are involved. As the pathway is associated with many essential functions in the body, its dysregulation is related to many diseases. In contrast to human pathology, a PubMed-search on Hippo, YAP/TAZ and companion animals (horse, equine, dog, canine, cat, feline) retrieved few publications. Because of its high level of functional conservation, it is anticipated that also in veterinary sciences aberrant Hippo YAP/TAZ signaling would be implicated in animal pathologies. Publications on Hippo YAP/TAZ in companion animals are mainly in cats and dogs and related to oncology. Here, we emphasize the important role of YAP/TAZ in liver diseases. First the liver has a remarkable regeneration capacity and a strict size control and the liver has a moderate liver cell renewal (homeostasis). The last years numerous papers show the importance of YAP/TAZ in hepatocellular carcinoma (HCC), hepatocyte differentiation and bile duct epithelial (BEC) cell survival. YAP/TAZ signaling is involved in activation of hepatic stellate cells crucial in fibrogenesis. The availability of drugs (e.g. verteporfin) targeting the YAP/TAZ pathway are described as is their potential usage in veterinary medicine. The aim of this overview is to stimulate researchers' and clinicians' interest in the potential role of Hippo YAP/TAZ signaling in veterinary medicine.

References

Callus B, Verhagen A, Vaux D . Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation. FEBS J. 2006; 273(18):4264-76. DOI: 10.1111/j.1742-4658.2006.05427.x. View

Ge M, Liu H, Zhang Y, Li N, Zhao S, Zhao W . The anti-hepatic fibrosis effects of dihydrotanshinone I are mediated by disrupting the yes-associated protein and transcriptional enhancer factor D2 complex and stimulating autophagy. Br J Pharmacol. 2017; 174(10):1147-1160. PMC: 5406384. DOI: 10.1111/bph.13766. View

Bisso A, Filipuzzi M, Gamarra Figueroa G, Brumana G, Biagioni F, Doni M . Cooperation Between MYC and β-Catenin in Liver Tumorigenesis Requires Yap/Taz. Hepatology. 2020; 72(4):1430-1443. DOI: 10.1002/hep.31120. View

Haak A, Kostallari E, Sicard D, Ligresti G, Choi K, Caporarello N . Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis. Sci Transl Med. 2019; 11(516). PMC: 7066514. DOI: 10.1126/scitranslmed.aau6296. View

Beffagna G, Sacchetto R, Cavicchioli L, Sammarco A, Mainenti M, Ferro S . A preliminary investigation of the role of the transcription co-activators YAP/TAZ of the Hippo signalling pathway in canine and feline mammary tumours. Vet J. 2015; 207:105-111. DOI: 10.1016/j.tvjl.2015.10.031. View

Panjehpour M, DeNovo R, Petersen M, Overholt B, Bower R, Rubinchik V . Photodynamic therapy using Verteporfin (benzoporphyrin derivative monoacid ring A, BPD-MA) and 630 nm laser light in canine esophagus. Lasers Surg Med. 2002; 30(1):26-30. DOI: 10.1002/lsm.10014. View

Rico C, Boerboom D, Paquet M . Expression of the Hippo signalling effectors YAP and TAZ in canine mammary gland hyperplasia and malignant transformation of mammary tumours. Vet Comp Oncol. 2018; 16(4):630-635. DOI: 10.1111/vco.12432. View

Huang J, Wu S, Barrera J, Matthews K, Pan D . The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005; 122(3):421-34. DOI: 10.1016/j.cell.2005.06.007. View

Liu-Chittenden Y, Huang B, Shim J, Chen Q, Lee S, Anders R . Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012; 26(12):1300-5. PMC: 3387657. DOI: 10.1101/gad.192856.112. View

10.

Guillemette S, Rico C, Godin P, Boerboom D, Paquet M . In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors. J Mammary Gland Biol Neoplasia. 2017; 22(3):203-214. DOI: 10.1007/s10911-017-9384-9. View

11.

Yuan W, Pepe-Mooney B, Galli G, Dill M, Huang H, Hao M . NUAK2 is a critical YAP target in liver cancer. Nat Commun. 2018; 9(1):4834. PMC: 6240092. DOI: 10.1038/s41467-018-07394-5. View

12.

Tschaharganeh D, Chen X, Latzko P, Malz M, Gaida M, Felix K . Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013; 144(7):1530-1542.e12. PMC: 3665638. DOI: 10.1053/j.gastro.2013.02.009. View

13.

Genevet A, Tapon N . The Hippo pathway and apico-basal cell polarity. Biochem J. 2011; 436(2):213-24. DOI: 10.1042/BJ20110217. View

14.

Yimlamai D, Christodoulou C, Galli G, Yanger K, Pepe-Mooney B, Gurung B . Hippo pathway activity influences liver cell fate. Cell. 2014; 157(6):1324-1338. PMC: 4136468. DOI: 10.1016/j.cell.2014.03.060. View

15.

Chan E, Nousiainen M, Chalamalasetty R, Schafer A, Nigg E, Sillje H . The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005; 24(12):2076-86. DOI: 10.1038/sj.onc.1208445. View

16.

Lo Sardo F, Strano S, Blandino G . YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting. Cancers (Basel). 2018; 10(5). PMC: 5977110. DOI: 10.3390/cancers10050137. View

17.

Corvaisier M, Bauzone M, Corfiotti F, Renaud F, El Amrani M, Monte D . Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse. Oncotarget. 2016; 7(35):56699-56712. PMC: 5302946. DOI: 10.18632/oncotarget.11057. View

18.

Justice R, Zilian O, Woods D, Noll M, Bryant P . The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995; 9(5):534-46. DOI: 10.1101/gad.9.5.534. View

19.

Zinsstag J, Schelling E, Waltner-Toews D, Tanner M . From "one medicine" to "one health" and systemic approaches to health and well-being. Prev Vet Med. 2010; 101(3-4):148-56. PMC: 3145159. DOI: 10.1016/j.prevetmed.2010.07.003. View

20.

Yu F, Zhao B, Panupinthu N, Jewell J, Lian I, Wang L . Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012; 150(4):780-91. PMC: 3433174. DOI: 10.1016/j.cell.2012.06.037. View